Advanced search
Publication Cover
Hematology Volume 17, 2012 - Issue 1
Submit an article Journal homepage
692
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL+ cells

Mahmoud HaririanDepartment of Hematology
,
Saeid KavianiDepartment of HematologyCorrespondence[email protected]
,
Masoud SoleimaniDepartment of Hematology
,
Soraya Rasi GhaemiDepartment of Anatomical SciencesSchool of Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran
,
Bahman DelalatDepartment of Hematology
&
Amir AtashiDepartment of Hematology
Pages 28-34 | Published online: 12 Nov 2013

References

  • Eaves CJ, Eaves AC. Stem cell kinetics. Baillieres Clin Haematol 1997;10:233–57.
  • Carella A M, Daley G Q, Eaves C J, Goldman J M, Hehlmann R, editors. Chronic myeloid leukaemia: biology and treatment. London: Martin Dunitz; 2001. p. 73–100.
  • Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83:2038–44.
  • Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the BCR gene and its role in the Ph9 translocation. Nature (Lond) 1985;315:758–61.
  • Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–56.
  • Kurzrock R, Gutterman JU, Taplaz M. The molecular genetics of Philadelphia positive leukemias. N Engl J Med 1988;319:990–8.
  • Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995;89:546–54.
  • Rapozzi V, Cogoi S, Xodo LE. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells. Mol Cancer Ther 2006;5:1683–92.
  • Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997;7:187–95.
  • Summerton J. Morpholino antisence oligos: applications in biopharmaceutical research. IPT 2005;17:32–7.
  • Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, et al.. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Natl Acad Sci USA 2005;102:1992–8.
  • Klee EW, Shim KJ, Pickart MA, Ekker SC, Ellis LB. AMOD: a morpholino oligonucleotide selection tool. Nucleic Acids Res 2005;33:506–11.
  • Apperley J. Mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007;8:1018–29.
  • Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia. Clin Exp Med 2006;6:45–7.
  • Withey JME, Harvey AJ, Crompton MR. RNA interference targeting of BCR-ABL increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin. Leuk Res 2006;30:553–60.
  • Taylor M, Paulauskis J, Weller D, Kobzik L. In vitro efficacy of Morpholino-modified antiscrise oligomers directed against tumor necrosis factor-alpha mRNA. J Biol Chem 1996;22:17445–52.
  • Collins S, Coleman H, Groudine M. Expression of bcr and bcr-abl fusion transcription in normal and leukemic cells. Mol Cell Biol 1987;7:2870–6.
  • Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 2001;61:2343–55.
  • Melo J, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Lett 2007;249:121–32.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.